Group 1 - WuXi AppTec's CAR-T drug, Rikeolunase injection, is expected to be included in the commercial health insurance innovation drug directory, marking a significant step in China's multi-tiered medical security system [1] - The drug is the first domestically approved Class 1 CAR-T therapy, with a pricing of 1.29 million yuan per injection, which aims to alleviate the pressure on basic medical insurance [1] - This breakthrough not only facilitates the realization of cutting-edge technology value but also promotes the formation of a complete closed loop from R&D to commercialization in the biopharmaceutical industry [1] Group 2 - Green Valley Pharmaceutical was fined 400,000 yuan for illegal promotion of the drug Ganluotena capsules (brand name: Jiuqi Yi), which has been controversial regarding its efficacy since approval [2] - The fine serves as a significant warning for pharmaceutical companies, especially for new drugs with low public awareness, emphasizing the importance of compliance in marketing practices [2] Group 3 - Libang Pharmaceutical has submitted its prospectus for an IPO on the Hong Kong Stock Exchange, focusing on the kidney disease sector as a global leading biopharmaceutical company [3] - The company has established a vertically integrated platform covering R&D, production, and commercialization, creating a core competitive advantage in a market with approximately 850 million kidney disease patients [3] Group 4 - Aidi Pharmaceutical's ADC118 tablets, a Class 1 new drug for HIV-1 treatment, have received clinical approval, marking the first domestically developed integrase inhibitor combination therapy to enter clinical trials in China [4] - This development represents a significant breakthrough in the research and development of new drugs for AIDS in China, potentially providing high-quality domestic treatment options for HIV patients [4] Group 5 - Lepu Biopharma's MRG003 (Vebecotuzumab) has been approved for marketing by NMPA, aimed at treating recurrent/metastatic nasopharyngeal carcinoma patients who have failed at least two lines of systemic chemotherapy and PD-1/PD-L1 inhibitors [5] - MRG003 is the world's first approved EGFR ADC new drug, marking a new milestone for domestic ADC products [5]